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Background: Estrogen causes proliferation of ovarian cancer cells. Although hormone therapy with an anti-
estrogen agent is an optional therapy for recurrent epithelial ovarian cancers, both basic and clinical researches are
insufficient. We here examine the efficacy of an aromatase inhibitor (AI) for peritonitis carcinomatosa, the late stage
of ovarian cancer.
Methods: Estrogen receptor (ER)α was assayed in four ovarian cancer cell lines by the RT-PCR method. Using
ovariectomized nude mice, peritonitis carcinomatosa consisting of OVCAR-3 cells with the strongest ERα expression
or DISS cells with weaker ERα expression was prepared. The survival period was compared between the letrozole
group (5 mg/kg/day orally; n = 10) and the control group (n = 10). In addition, the degree of angiogenesis and
occurrence of apoptosis were compared using tumor tissue from the abdominal cavity. The expression of aromatase
and the protein involving in ERα signaling were examined in tumors immunohistochemically.
Results: Survival period in OVCAR-3 tumors was significantly prolonged in the letrozole group, compared with the
control group (P < 0.05), whereas that in DISS tumors was not different between the both groups. The microvessel
density in tumors and expression of VEGF decreased significantly in the letrozole group compared to the control
group. The incidence of apoptosis did not differ significantly between these groups. No adverse event was observed
accompanying the administration of letrozole. The expressions of aromatase, ERα and FOXP1 that is associated with
ERα signaling were reduced in tumors by letrozole administration.
Conclusions: Letrozole was effective for ovarian cancers with abundant expression of ERα. Inhibition of angiogenesis
and of ascites production appeared to contribute to prolongation of the survival period.
Keywords: Recurrent ovarian cancer, Letrozole, Estrogen receptor alpha, Aromatase inhibitor, Anti-angiogenesisBackground
Ovarian cancer is still the most lethal of all gynecologic
cancers. The American Cancer Society estimated that
about 22,240 new cases of ovarian cancer will be diag-
nosed and 14,030 women will die of ovarian cancer in
the United States in 2013 [1]. There are various methods
for treating of recurrent ovarian cancer and chemothera-
peutic regimen is chosen based on platinum suscepti-
bility but there is no established second-line therapy.* Correspondence: yokoyama@cc.hirosaki-u.ac.jp
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stated.In the National Comprehensive Cancer Network
(NCCN) guidelines (version 3, 2012), hormone therapy is
classified under “other drugs that are potentially effective”
as “approved treatment for recurrent forms” of epithelial
ovarian cancer. However, the number of clinical and basic
studies of hormone therapy conducted for this disease is
insufficient.
There is evidence that estrogen promotes proliferation
of ovarian cancer in cell culture and a xenograft model
[2-6]. Furthermore, it has been shown that the growth of
ovarian cancer cells is inhibited in vivo and in vitro by
the anti-estrogen therapy directed at estrogen receptor
(ER) positive OVCAR-3 cells [3,5,6].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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up to 60% of ovarian cancers [7]. ERα activates expression
of genes that are involved in cell survival and proliferation,
whereas the function of ERβ has been found to be anti-
proliferative [8]. Because the growth response in ovarian
cancer cell lines is mediated by ERα but not by ERβ [5,9],
treatment with an ERα specific agonist (PTT,4′,4′,4″-
(4-(4-Propyl-[1H]-pyrazole-1,2,5-tryl)trisphenol) promotes
cell proliferation [5].
Aromatase converts adrenal androstenedione to estro-
gen and is expressed in fat, liver, muscle and cancers such
as the breast and the ovary [10]. Intra-tumoral estrogens
derived from in situ aromatization act as an autocrine
growth factor that promotes cancer cell proliferation inde-
pendent of circulating estrogen [11]. Aromatase inhibitors
(AIs) inhibit estrogen production in postmenopausal
women by more than 90%. Expression of aromatase
mRNA and the aromatase protein itself have been found
in 33-81% of ovarian cancers [12,13].
The therapeutic effect of AIs has been shown to be
superior to that of tamoxifen as adjuvant therapy for
breast cancer [14]. In addition, in vitro studies showed
an anti-tumor effect of AI on ovarian cancer cells, which
was associated with aromatase activity and ER expres-
sion [15]. Letrozole is an oral non-steroidal AI and used
for the treatment of local or metastatic breast cancer
that is ER positive.
The present study was conducted to evaluate the effi-
cacy of letrozole in the late stages of ERα positive ova-
rian cancer and elucidate the mechanism.
Methods
Cell cines and cell culture
OVCAR-3 derived from human ovarian papillary adeno-
carcinoma and TOV-112D derived from human ovarian
endometrioid adenocarcinoma were obtained from the
American Type Culture Collection (Rockville, MD).
MCAS derived from human ovarian mucinous adeno-
carcinoma was obtained from Japanese Collection of
Research Bioresources Cell Bank (Osaka, Japan). DISS
derived from human ovarian serous adenocarcinoma
was kindly provided by Dr. Saga (Jichi Medical School,
Tochigi, Japan) [16]. All of these cell lines were grown
in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 100 U/ml penicillin and 100 μg/ml
streptomycin at 37°C in a water-saturated atmosphere
with 5% CO2/95% air. All cell lines used in this study
are authenticated as being ovarian in origin with a writ-
ten guarantee.
Animal experimentation
Animal experiments were conducted in accordance with
the Guidelines for Animal Experimentation, Hirosaki
University. Eight-week-old female BALB/c nu/nu micewere used in this study. At the Institute for Animal
Experimentation of Hirosaki University, all mice were
group-housed in plastic cages with stainless-steel grid
tops, under a 12-hour light dark cycle and consumed
water and food ad libitum.
Hormone administration and ovariectomy
Letrozole was purchased from Novartis Oncology (Tokyo,
Japan). Letrozole was suspended in distilled water
(0.88 mmol/l). The experimental mice were divided into
two groups containing ten mice each. The letrozole
group was given letrozole 5 mg/kg/day by oral gavage
every day until the end of the study, and the control
group was given vehicle. Bilateral ovariectomy was per-
formed under pentobarbital anesthesia in all experimen-
tal mice on the seventh day after commencement of
letrozole administration.
Real-time quantitative PCR
Total RNA was extracted from the cells using an Illustra
RNAspin Mini RNA Isolation Kit (GE Healthcare,
Piscataway, NJ). Total RNA (4 μg) served as a template
for single-strand cDNA synthesis in a reaction using an
iScript Advanced cDNA Kit (Bio-Rad, Hercules, CA)
under the conditions [17] with slight modifications. A
CFX96 real-time PCR detection system (Bio-Rad) was used
for the quantitative analyses of ERα and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The sequences of the





The amplification reactions were performed with SsoFast
EvaGreen Supermix (Bio-Rad) according to the manu-
facturer’s specifications. The primers were used at 300 nM.
The amplification conditions were as follows: 30 sec at
95°C, followed by 95°C for 5 sec and 60°C for 30 sec for
40 consecutive cycles. After amplification, a melting curve
65°C to 95°C at 0.5°C increments and 5 sec per step was
generated with continuous monitoring of fluorescence.
The melting curves and quantitative analysis of the data
were performed using CFX manager Version 2.1 software
(BioRad) [17].
Evaluation of adverse effects following administration of
letrozole
The nude mice, ovariectomized at the age of nine weeks
were given letrozole (n = 10) or its vehicle (n = 10) for
five weeks. All mice were weighed every day and the
consumption of food was measured daily. Acts of self-
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OVCAR-3 cells (5.0 × 106 cells) or DISS cells (5.0 × 106
cells) were inoculated into the peritoneal cavity of ovariec-
tomized nude mice in 500 μl of RPMI 1640 medium at
the age of nine weeks. The survival times for the letrozole
and control groups were evaluated. The survival was com-
pared until 5 weeks after cell inoculation and surviving
mice were euthanized using high-dose pentobarbital in
order to remove the peritoneal tumors for histologic and
biochemical evaluation.
Immunohistochemical analysis and microvessel density
Six-micrometer sections of formalin-fixed and paraffin-
embedded tissue specimens were stained by an established
method described previously [18]. Sections were incu-
bated with antibodies specific for Factor VIII (DAKO,
Tokyo, Japan), vascular endothelial growth factor (VEGF)
(R & D Systems, Minneapolis, MN), cleaved caspase-3
(Santa Cruz Biotechnology, Santa Cruz, CA), human P450
aromatase (ARK Resource, Kumamoto, Japan), ERα (Santa
Cruz Biotechnology) and FOXP1 (Abcam, Tokyo, Japan)
at 4°C overnight. Slides were incubated with biotinylated
species-specific appropriate secondary antibodies for
30 minutes and exposed to avidin-biotin-peroxidase
complex (VECTA Laboratories, Burlingame, CA). Sec-
tions were treated with 0.02% DAB as a chromogen and
counterstained with hematoxylin. Microvessel density
(MVD) was determined as follows. The highly vascula-
rized areas of the tumor stained with an anti-Factor VIII
antibody were identified and Factor VIII-positive micro-
vessels were counted within a high-power field (number
per 0.75 mm2). Single endothelial cells or clusters of
endothelial cells, with or without lumen, were con-





























Figure 1 Determination of estrogen receptor-alpha (ERα) mRNA
level in four ovarian cancer cell lines. The level of ERα mRNA was
significantly higher in OVCAR-3 cells in comparison to the other
three lines. ERα mRNA expression was normalized to GAPDH mRNA
expression (DISS as control = 1). Means ± SD of three experiments
are shown. * P < 0.05 versus OVCAR-3.vessel number/high-power field in sections. Three fields
were counted per animal and the average was taken as
the MVD of each tumor.
Weatern blot analysis
Cell lysates (50 μg protein) were prepared from tumor tis-
sues, electrophoresed through a 12.5% SDS-polyacrylamide
gel, and blotted as described previously [18]. The protein
concentration was determined using Bradford’s method.
The blots were probed with the following diluted anti-
bodies for 2 hr: cleaved caspase-3 (active, 17KDa) at
1:1000 and β-actin (Sigma-Aldrich, St Louis, MO) at
1:2000. The membranes were then incubated for 1 hr with
the appropriate biotinylated secondary antibodies, trans-
ferred to avidin-biotin-peroxidase complex reagent, and
incubated in this solution for 30 min. Diaminobenzidine






















Figure 2 Comparison of the survival period in the letrozole
group and the control group. (A) Appearances, intraperitoneal
finding and bloody ascites of peritoneal carcinomatosa mice model
derived from OVCAR-3 cells. Asterisks show disseminated foci of the
cancer. (B) The survival period in the letrozole group was extended
significantly beyond that in the control group in ERα positive
OVCAR-3 tumors (P < 0.05). (C) There was no signicant difference in
survival period between the groups in ERα negative DISS tumors.
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Survival rates were calculated by the Kaplan-Meier
method, and the statistical significance of differences in
the cumulative survival curves between the groups was
evaluated using the log-rank test. Other statistical ana-
lysis was carried out with the Student t-test. A result
was deemed significant at a P value < 0.05.Results
Comparison of mRNA expression of ERα in the ovarian
cancer cell lines
We determined mRNA abundance of ERα in four ova-
rian cancer cell lines using real-time quantitative PCR.
We found that the level of ERα mRNAin OVCAR-3
cells was significantly higher than that in other three
cell lines (P < 0.05, Figure 1). Thus, OVCAR-3 was de-
fined as ERα positive, whereas DISS, MCAS and TOV-




Figure 3 Comparison of expression of aromatase, ERα and FOXP1 in
Immunohistochemical staining shows descreased expression of aromatase,Evaluation of adverse effect caused by giving letrozole
after ovariectomy
Changes in the body weights of ovariectomized mice
were evaluated. Body weights were 27.9 ± 1.4 in mice
given letrozole for 5 weeks and 28.1 ± 2.4 in mice given
vehicle, with no significant difference. All of the mice
were healthy and did not exhibit self-harm or act
aggressively.Comparison of survival period in peritonitis
carcinomatosa derived from OVAR-3 cells or DISS cells
Survival times were compared between the letrozole
and the control groups in the peritonitis cacinomatosa
(Figure 2A). Survival periods in ERα positive OVCAR-3
tumors were significantly prolonged in the letrozole
group, compared with the control group (P < 0.05,
Figure 2B), whereas those in ERα negative DISS tumors
were not different between the both groups (Figure 2C).Letrozole
tumors between the control and letrozole groups.
ERα and FOXP1 by letrozole administration, compared to the control.
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tumors by letrozole
We compared aromatase expression in tumors in order to
examine whether letrozole administration affects in situ
aromatization. Expressions of ERα and FOXP1 involving
in ERα signaling [19] were also examined. Immunohisto-
chemical analysis showed that expression of aromatase,
ERα and FOXP1 in tumors was reduced by letrozole
administration (Figure 3).
Reduction of microvessel density and VEGF level in
tumors by letrozole
We examined the number of microvessels identified in
tumor tissues using an immunostaining method for Factor
VIII. MVD (number/mm2) was 8.9 ± 1.4 for the control
group, and 5.8 ± 1.8 for the letrozole group, showing a sig-
nificant decrease in the letrozole group as compared with
the control group (P < 0.05, Figure 4A). Immunostaining






















Figure 4 Comparison of microvessel density (MVD) and VEGF express
the letrozole group was significantly lower than that in the control group.
lower than that in the control group.tumors in the letrozole group, as compared with the con-
trol group (Figure 4B).
Comparison of apoptotic cells identified with caspase-3
antibody and expression of caspase-3
The number of apoptotic cells per mm2 was 320 ± 32 in
the control group, and 272 ± 32 in the letrozole group, an
insignificant difference between the groups (Figure 5A).
Western blot also showed no significant difference of
expressions of caspase-3 between the groups (Figure 5B).
Discussion
In this study, we prepared a model of peritonitis carcino-
matosa, using ovariectomized nude mice and examined
the effect of an AI on this condition, which occurs most
frequently as a mode of postoperative recurrence of ovar-
ian cancer. We found that the survival was extended sig-
nificantly by the administration of letrozole in peritonitis




ion in the letrozole group and the control group. (A) The MVD in










Figure 5 Apoptotic cells identified with caspase-3 antibody and expression of caspase-3. (A) Immunohistochemical staining. Brown-colored
cells are an apoptotic cell identified with caspase-3 antibody. (B) Western blot. There is no significant difference in expressions of caspase-3 between
the groups.
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chanism of action, decreases in MVD and VEGF ex-
pression suggested that inhibition of both angiogenesis
and production of ascites contributed to prolongation of
survival.
It has been reported that VEGF plays an important
role in angiogenesis and ascites production and the ex-
pression of VEGF is regulated by estrogen [20]. Presence
of an estrogen-responsive element was established for
the VEGF gene [21], and the contribution of estrogen to
a direct increase in expression of the VEGF gene and
angiogenesis has been demonstrated [22]. These results
therefore indicate that estrogen accelerates tumor pro-
gression by means of VEGF. Conversely, AIs are shown
to decrease the estrogen level in breast cancer tissues
[23] and reduce VEGF in breast cancer cells [24]. The
present study shows for the first time that the adminis-
tration of an AI decreased VEGF and MVD in OVCAR-
3 that is derived from ovarian cancer. The present re-
sults provide evidence for inhibition of angiogenesis by
the AI and indicate that inhibition of angiogenesis is the
mechanism by which AIs suppress tumor proliferation.
In breast cancers, estrogen and ER are involved in tumor
proliferation and tumor proliferation is inhibited by the
anti-estrogen activity [25]. Although it has not been
shown in ovarian cancers that estrogen and ER areinvolved in tumor proliferation in a similar manner to
breast cancers, an effect of AIs on ER-positive ovarian
cancer can be expected based on the results of this
study, which demonstrated inhibition of tumor prolifera-
tion in ERα-positive ovarian cancers by the AI. In this
study, expression of aromatase, ERα and FOXP1 in
OVCAR-3 tumors was reduced by letrozole administra-
tion. Aromatization of androstendione may be inhibited
in OVCAR-3 tumors by letrozole. FOXP1 is situated at a
downstream of ERα signaling [19]. These results suggest
that suppression of aromatization and ERα signaling in
ERα-positive ovarian cancer by the AI may contribute to
inhibition of tumor proliferation.
In vitro experiments using breast cancer cells have
shown an induction of apoptosis by AIs [26], indicating
that this is the mechanism of inhibition of breast cancer
proliferation. AIs have also been reported to increase
in vivo apoptosis significantly in combination with an
mTOR inhibitor, thereby exhibiting an anti-tumor effect
[27]. Amarai et al. have emphasized the importance of
AIs as inducers of apoptosis, by effects on both mito-
chondria and caspase-8 [28]. On the other hand, Bailey
et al. have reported that the combination of an AI and
an apoptosis inducer is an effective treatment strategy
for ER-positive breast cancers, as ERs inhibit p53-
induced apoptosis but AIs block the signaling of ERs
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favorable to apoptosis by inhibiting the activity of ERs,
although they did not inhibit apoptosis directly [29]. The
results of our study, which did not show a significant
increase in apoptosis in ovarian tumors following the ad-
ministration of an AI, agree with the results of Bailey et al.
AIs have been shown to be more effective than tamoxi-
fen if they are used as postoperative adjuvant therapy in
breast cancers [30]. No definite conclusion, however, has
yet been reached with regard to the effect of AIs in recur-
rent ovarian cancers. The effects of AIs on in vitro ovarian
cancer cells were related to aromatase activity and estro-
gen receptor expression [6]. Of four clinical studies that
have verified the efficacy of letrozole in recurrent ovarian
cancers [31-34], three clinical studies conducted in pa-
tients with ERα-positive recurrent ovarian cancers showed
that the response rate to letrozole was 11.8% in the 102
patients [31-33]. However, the details of progression-free
survival or overall survival are unknown. Adverse reac-
tions to letrozole were slight compared to those of anti-
cancer agents and the response rate of 11.8% is similar to
that obtained with salvage chemotherapy. As shown in
Figure 3, letrozole has an inhibitory effect on angiogenesis,
therefore it is expected that patients with ERα-positive re-
current ovarian cancers are candidates of letrozole admin-
istration alone or in combination with bevacizumab, a
drug that targets molecules involved in angiogenesis.
Estrogen accelerates angiogenesis and is involved in
the progression of tumors [35]. ER signaling inhibits
apoptosis [29]. Letrozole, an AI, has been shown to ex-
hibit an antitumor effect by inhibiting angiogenesis in
ERα-positive ovarian cancers and by inhibiting the ac-
tions of ERα. Although the effect of letrozole on survival
was statistical significant in mice, it is an important issue
whether the clinical significance of the findings will be
achieved. Thus, further investigation of whether Letro-
zole sensitizes OVCAR-3 tumour to platinum com-
pound is warranted. AIs will likely play a central role in
the establishment of a new treatment strategy in ERα-
positive ovarian cancers in the future. Clinical trials of
letrozole alone or in combination with other molecular
targeted drugs will be required to further evaluate the
drug’s efficacy in the treatment of ERα-positive ovarian
cancers.
Conclusions
Letrozole was effective for peritonitis carcinomatosa as a
late stage of ovarian cancer with abundant expression of
ERα. Inhibition of angiogenesis and of ascites production
appeared to contribute to prolongation of the survival
period.
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